The NBER Orange Book Dataset: A user’s guide

Research Policy - Tập 52 - Trang 104791 - 2023
Maya Durvasula1, C. Scott Hemphill2, Lisa Larrimore Ouellette3, Bhaven Sampat4, Heidi L. Williams1
1Department of Economics, Stanford University, United States of America
2NYU School of Law, United States of America
3Stanford Law School, United States of America
4Department of Health Policy and Management, Columbia University, United States of America

Tài liệu tham khảo

Ark Patent Intelligence, 2019 Azoulay, 2019, Public R&D investments and private-sector patenting: Evidence from NIH funding rules, Rev. Econom. Stud., 86, 112, 10.1093/restud/rdy034 Branstetter, 2016, Regulation and welfare: Evidence from paragraph IV generic entry in the pharmaceutical industry, Rand J. Econ., 47, 857, 10.1111/1756-2171.12157 Cohen, 2000 Eisenberg, 2012, Patents and regulatory exclusivity Frakes, 2022, Investing in ex ante regulation: Evidence from pharmaceutical patent examination, Am. Econ. J. Econ. Policy Gupta, Charu N., 2021. One Product, Many Patents: Imperfect Intellectual Property Rights in the Pharmaceutical Industry. Working Paper. Hemphill, 2011, When do generics challenge drug patents?, J. Empir. Leg. Stud., 8, 613, 10.1111/j.1740-1461.2011.01235.x Hemphill, 2012, Evergreening, patent challenges, and effective market life in pharmaceuticals, J. Health Econ., 31, 327, 10.1016/j.jhealeco.2012.01.004 Hemphill, 2013, Drug patents at the supreme court, Science, 339, 1386, 10.1126/science.1235857 Kapczynski, 2012, Polymorphs and prodrugs and salts (oh my!): An empirical analysis of ‘secondary’ pharmaceutical patents, PLoS One, 7, 10.1371/journal.pone.0049470 Kesselheim, 2017, Determinants of market exclusivity for prescription drugs in the United States, JAMA Intern. Med., 177, 1658, 10.1001/jamainternmed.2017.4329 Kyle, Margaret, Sampat, Bhaven N., Shadlen, Kenneth C., 2020. TRIPS, Patents, and Drug Prices in India. Working Paper. Lemley, 2015, Probabilistic patents, J. Econ. Perspect., 19, 75, 10.1257/0895330054048650 Lemley, 2022, What litigators can teach the patent office about pharamaceutical patents, Wash. Univ. Law Rev., 99, 1673 Levin, 1987, Appropriating the returns from industrial research and development, Brook. Pap. Econ. Act., 783, 10.2307/2534454 Lietzan, 2020, Distorted drug patents, Wash. Law Rev., 95, 1317 de Rassenfosse, 2018 Sampat, 2015, TRIPS implementation and secondary pharmaceutical patenting in Brazil and India, Stud. Comp. Int. Dev., 50, 228, 10.1007/s12116-015-9181-7 Thomas, 2017